Article Text
PDFTherapeutics/Prevention
Systematic review with meta analysis
Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes
Statistics from Altmetric.com
Footnotes
Competing interests DWJ has previously received consultancy fees, research grants, speaker's honoraria and travel sponsorships from Amgen, Roche and Janssen-Cilag.
Provenance and peer review Commissioned; internally peer reviewed.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/